Flu Forward: Influenza innovation for healthy ageing
19 Nov, 2026
DOWNLOAD REPORT: Flu Forward consensus statement
Growing evidence demonstrates that vaccines - including flu vaccines - are now going beyond their traditional scope of preventing infectious disease and can also reduce the risk of non-communicable diseases (NCDs), offering profound public health benefits. To maximise these population-wide outcomes, policymakers should champion vaccination as a vital, dual-purpose strategy for both infection control and NCD prevention.
Influenza (flu) is not only a respiratory illness. It can trigger heart attacks, strokes and heart failure, so preventing flu is also cardiovascular prevention. Using more adapted flu vaccines has the potential not only to prevent flu but also to produce wider benefits, including a reduction in all-cause hospitalisations and healthcare costs.
The Flu Forward project explores how adopting specifically tailored flu vaccines could support health systems. Through this project, the ILC has spoken with experts across Europe to form a consensus statement on how best to utilise these vaccines to support healthy ageing.
The consensus statement is backed by new ILC modelling based on FLUNITY-HD – a trial of more than 466,000 people aged 65 and over in Denmark and Spain, published in The Lancet in October 2025. ILC’s new findings compare high-dose flu vaccines with non-adjuvanted standard-dose vaccines across France, Germany, Italy, Japan and the UK. Our analysis finds that:
- Switching from non-adjuvanted standard-dose to high-dose vaccines at today’s uptake could prevent 109,000 hospital admissions among people aged 65 and over across the five countries, saving €683 million in direct hospital costs.
- Raising uptake to the 75% benchmark would prevent a further 38,000 admissions – 147,000 in total.
- Offering high-dose vaccination from age 50 at 75% uptake could prevent 271,000 admissions and save €1.7 billion (2025 prices). This scenario is exploratory, as the trial enrolled only people aged 65 and over.
- In the three EU countries alone – France, Germany and Italy – that would mean around 139,000 fewer admissions and €836 million in hospital savings.
- Germany has the most to gain: its savings would more than triple, from €118 million to €428 million. Just 40% of Germans aged 65 and over were vaccinated against flu in 2024.
Our consensus statement calls for health stakeholders and policymakers to:
Position flu vaccination as core prevention for healthy ageing: Recognise flu as a serious risk as we age and for people who are clinically vulnerable, not a minor seasonal illness. Take a life course approach and embed flu vaccination in healthy ageing plans, NCD strategies (such as the EU’s Safe Hearts Plan) and respiratory health plans, to reduce all-cause and cardiorespiratory hospitalisations and ease winter pressures. Reflect the full system benefits of reduced hospitalisation and wider societal costs within health technology assessment and budget planning. Improve surveillance of uptake, effectiveness and outcomes to capture the wider economic benefits.
Make flu vaccination part of cardiovascular prevention: Cardiology societies and health ministries should include annual flu vaccination in cardiovascular guidelines, care pathways and secondary prevention, alongside other risk-reduction measures. Make it standard practice in respiratory, diabetes and multimorbidity pathways too, with specialists taking responsibility for vaccination and vaccinating patients in accessible settings. Commit to cross-sector leadership to embed flu prevention within long-term healthy ageing frameworks, and carry EU policy frameworks through into national healthcare delivery mechanisms.
Give older adults access to vaccines that offer better protection against flu and its complications: Ensure access to age-appropriate vaccines, including formulations where evidence shows superior protection, and to new vaccines and technology that are leading to good outcomes.
Drive high and equitable uptake through access and positive communication: Set ambitious coverage targets and address inequalities in access, awareness and confidence. Remove barriers, including out-of-pocket costs, and make access universal through pharmacies and, for clinical risk groups, hospitals. Healthcare professionals should use positive language that focuses on quality of life rather than mortality and makes clear what patients gain from vaccination. Involve health groups and patient organisations in vaccine communications, and learn from other NCD communities.
Consider lowering the flu vaccination eligibility age to 50: Review national eligibility criteria with a view to offering flu vaccination from age 50. Our modelling suggests that, with a more adapted vaccine, this could prevent many more hospital admissions and protect a broader cohort of adults for longer, while they are still economically active.
Sanofi has provided a financial contribution in the form of a grant to ILC’s “Flu Forward: Influenza Innovation for Healthy Ageing” project. ILC retains full editorial control over all project materials.

